Despite the ongoing litigation with originator Astellas, Lupin decided not to wait around and launch its 50mg generic rival to Myrbetriq (mirabegron).
Lupin Launches Higher Mirabegron Dose ‘At-Risk’
The 25mg Dose Was Launched Back In April, Also ‘At-Risk’
Lupin and Zydus have established a two-player market for their generic versions of mirabegron, while patent litigation with originator Astellas continues on.
More from Products
More from Generics Bulletin
• By
Off-patent drug trade groups expressed their concerns that personnel and expertise cuts will affect the agency’s ability to review and approve generics and biosimilars.
• By
Amid ongoing generic drug supply problems, Japan's government is to set up a new fund to support corporate investments geared towards manufacturing and consolidation.
• By
FDA staffing cuts are making negotiation preparations more difficult, but also could mean the result is a smaller user fee renewal package.